Thyroid Cancer clinical trials in Washington

9 actively recruiting thyroid cancer trials at 27 sites across Washington.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 1, Phase 2 Recruiting Industry

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…

Sponsor: Turning Point Therapeutics, Inc.

NCT ID: NCT03093116

Sites in Washington:

Local Institution - 2107 — Seattle, Washington
Local Institution - 2141 — Tacoma, Washington

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier

NCT ID: NCT05786924

Sites in Washington:

Fred Hutchinson Cancer Research Center — Seattle, Washington

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less …

Sponsor: Children's Hospital of Philadelphia

NCT ID: NCT05783323

Sites in Washington:

Seattle Children's Hospital — Seattle, Washington

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Sponsor: Children's Hospital of Philadelphia

NCT ID: NCT06458036

Sites in Washington:

Seattle Children's Hospital — Seattle, Washington

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…

Sponsor: Pfizer

NCT ID: NCT05538130

Sites in Washington:

Fred Hutchinson Cancer Center — Seattle, Washington
University of Washington Medical Center — Seattle, Washington

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

SLV-154 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Sponsor: Solve Therapeutics

NCT ID: NCT06771219

Sites in Washington:

University of Washington / Fred Hutchinson Cancer Center — Seattle, Washington
Northwest Medical Specialties, PLLC — Tacoma, Washington

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Washington:

Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
Highline Medical Center-Main Campus — Burien, Washington
Providence Regional Cancer System-Centralia — Centralia, Washington
Swedish Cancer Institute-Edmonds — Edmonds, Washington

View on ClinicalTrials.gov →

NA Recruiting Network

Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.

Sponsor: Eastern Cooperative Oncology Group

NCT ID: NCT05108298

Sites in Washington:

Overlake Medical Center — Bellevue, Washington
Highline Medical Center-Main Campus — Burien, Washington
Saint Elizabeth Hospital — Enumclaw, Washington
Saint Francis Hospital — Federal Way, Washington
Saint Clare Hospital — Lakewood, Washington

View on ClinicalTrials.gov →

Recruiting Academic/Other

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females. Recently targeted drugs that block many of the genetic drivers of DTC ha…

Sponsor: Children's Hospital of Philadelphia

NCT ID: NCT05024929

Sites in Washington:

Seattle Children's Hospital — Seattle, Washington

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20